Vanguard Group
ABOS icon

Vanguard Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Vanguard Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.49M Buy
1,653,772
+2,300
+0.1% +$4.56K ﹤0.01% 3389
2025
Q3 		$2.82M Sell
1,651,472
-37,879
-2% -$52.4K ﹤0.01% 3463
2025
Q2 		$1.96M Sell
1,689,351
-247,640
-13% -$266K ﹤0.01% 3537
2025
Q1 		$2.13M Sell
1,936,991
-3,780
-0.2% -$5.4K ﹤0.01% 3475
2024
Q4 		$3.34M Buy
1,940,771
+6,732
+0.3% +$16.2K ﹤0.01% 3410
2024
Q3 		$4.8M Buy
1,934,039
+37,090
+2% +$101K ﹤0.01% 3286
2024
Q2 		$4.59M Buy
1,896,949
+231,891
+14% +$738K ﹤0.01% 3295
2024
Q1 		$6.74M Sell
1,665,058
-174,494
-9% -$658K ﹤0.01% 3169
2023
Q4 		$7.06M Sell
1,839,552
-17,000
-0.9% -$50.5K ﹤0.01% 3138
2023
Q3 		$7.7M Buy
1,856,552
+1,121,700
+153% +$6.93M ﹤0.01% 3045
2023
Q2 		$3.53M Buy
734,852
+115
+0% +$551 ﹤0.01% 3462
2023
Q1 		$2.98M Buy
734,737
+18,900
+3% +$98.7K ﹤0.01% 3528
2022
Q4 		$3.87M Buy
715,837
+64,791
+10% +$435K ﹤0.01% 3427
2022
Q3 		$6.53M Buy
651,046
+15,267
+2% +$87.6K ﹤0.01% 3173
2022
Q2 		$2.99M Sell
635,779
-598,992
-49% -$2.25M ﹤0.01% 3629
2022
Q1 		$4.83M Buy
1,234,771
+679,798
+122% +$3.7M ﹤0.01% 3547
2021
Q4 		$3.75M Sell
554,973
-769,925
-58% -$8.46M ﹤0.01% 3773
2021
Q3 		$19.7M Buy
+1,324,898
New +$22M ﹤0.01% 2873

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Vanguard Group's ABOS Position: Q4 2025 in Review

Vanguard Group increased its Acumen Pharmaceuticals (ABOS) stake by 0.14% in Q4 2025, buying an estimated $4.56K and bringing the position to 1,653,772 shares worth $3.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

Vanguard Group first reported a position in ABOS in Q3 2021 and has held it in 18 quarters since. The position peaked at $19.7M in Q3 2021. 71 funds tracked by Wall St. Rank hold ABOS as of Q4 2025.

  • Vanguard Group held 1,653,772 shares of Acumen Pharmaceuticals worth $3.49M as of Q4 2025.
  • Vanguard Group bought 2,300 Acumen Pharmaceuticals shares in Q4 2025, an estimated $4.56K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3389 holding.
  • Vanguard Group first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • Vanguard Group's Acumen Pharmaceuticals position peaked at $19.7M in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.